FDA re­buffs lit­tle As­ser­tio Ther­a­peu­tic­s' long-act­ing ACTH for­mu­la­tion, shares sink

Tiny As­ser­tio Ther­a­peu­tics’ shares plunged pre-mar­ket on Tues­day, af­ter the FDA has spurned its man-made ver­sion of the hor­mone ACTH, which was be­ing re­viewed as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.